Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

Clinical trial NCT04938232 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04938232
Sponsor: Dana-Farber Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hodgkin Lymphoma Relapsed Hodgkin's Disease, Adult Refractory Hodgkin Lymphoma

Start date: 2021-06-04
Primary completion: 2024-04-01
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.